NCT02052349

Bioavailability of ABT-333 Within the Gastrointestinal Tract in Healthy Subjects

A Phase I, Open-Label Study to Investigate the Regional Bioavailability of ABT-333 When Delivered to Different Sites Within the Gastrointestinal Tract in Healthy Subjects

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 12 (actual)
• Sponsor: AbbVie · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This open label, Phase 1 study is to investigate the relative bioavailability of ABT-333 when delivered within different sites of the gastrointestinal tract in 12 healthy subjects.

Detailed description

Bioavailability of ABT-333 in different areas of the gut

Conditions

• Relative Bioavailability

Interventions

Type	Name	Description
DRUG	ABT-333	Dose of ABT-333

Timeline

• Start date: 2013-11-01
• Primary completion: 2013-12-01
• Completion: 2013-12-01
• First posted: 2014-02-03
• Last updated: 2014-02-03

Locations

1 site across 1 country: United Kingdom